Oncolys BioPharma Inc. announced that the World Health Organization selected the recommended International Nonproprietary Name (INN) for "Telomelysin (OBP-301)", oncolytic viral immunotherapy. International nonproprietary name of Telomelysin (OBP-301): suratadenoturev. Decision of the INN by WHO is an important step towards obtaining approval of a new drug, and the name, suratadenoturev will be used for Telomelysin in the world. The registration procedures in the United States (USAN: United States Adopted Names) will be followed. Oncolys develops Telomelysin based on the concept of "cure without surgery". Oncolys will promote research and development on the combination of Telomelysin and other treatments and aims to contribute to the development of cancer treatments that will help in the medical field.